Ivarmacitinib for palmoplantar pustulosis
Treatments studied
Part of Skin clinical trials.
This trial tests a new oral medication, ivarmacitinib, for adults with palmoplantar pustulosis (PPP) who haven't gotten better with standard treatments. It aims to see if the drug is safe and effective for reducing the painful pustules on the palms and soles.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have palmoplantar pustulosis (PPP), diagnosed by a doctor or skin biopsy
- You have tried at least one standard treatment for 12 to 24 weeks and it did not work or caused side effects
- Your doctor thinks ivarmacitinib might be a good option for you
- You do not have serious problems with your blood counts, kidneys, or liver
- You do not have an active infection (like tuberculosis, hepatitis B/C, or widespread yeast infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tofacitinib and imatinib) for people with moderate-to-severe palmoplantar pustulosis, a painful skin condition affecting the palms and soles. The goal is to see if this combo can reduce pustules and improve symptoms.
This study tests a new drug (Xeligekimab) for people with moderate to severe palmoplantar pustulosis — a condition causing painful blisters on the hands and feet. It may be an option if other treatments haven't worked well.
This trial tests a new medication called picankibart for palmoplantar pustulosis, a skin condition causing painful pustules (small fluid-filled bumps) on the palms and soles. It's designed for people whose condition hasn't improved with standard treatments.
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
This trial tests a drug called bimekizumab for people with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal is to see if the drug can clear these pustules and improve symptoms.
This trial tests a new oral medication called Ivarmacitinib for people with moderate-to-severe atopic dermatitis (a type of eczema). The goal is to see if it helps reduce symptoms and improve skin condition.
Hear when a new Palmoplantar Pustulosis (PPP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.